Medjet, Inc.

Ticker: MJETC		1090 King Georges Post Road, Suite 301
Exchange: Over-the-Counter Market		Edison, New Jersey 08837
Industry: Manufacturing		(908) 738-3990

Type of Shares:	Common Shares	Filing Date:	7/23/96
U.S. Shares:	1,100,000	Offer Date:	8/7/96
Non-U.S. Shares:	0	Filing Price:	$5.60
Primary Shares:	1,100,000	Offer Price:	$5.60
Secondary Shares:	0	Gross Spread:	$0.56
Offering Amount:	$6,160,000	Selling:
Expenses:	-	Reallowance:
Shares Out After:	3,521,741

Manager	Tier	Phone
Patterson Travis, Inc.	Lead Manager	(212) 837-7340

	Audited Income	Latest Unaudited Income	Prior Unaudited Income		Balance Sheet
	12/31/95	3/31/96	3/31/95		3/31/96
Revenue:	$0.00	$0.00	$0.00	Assets:	$0.35
Net Income:	-$0.68	$0.18	-$0.15	Liabilities:	$0.53
EPS:	-$0.28	-$7.00	-$0.06	Equity:	-$0.18
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year

Business Description

Medjet Inc., founded in December 1993, has developed a proprietary surgical device known as a keratome, which utilizes a hair thin circular beam of supersonic velocity water. The waterjet beam substitutes for a conventional metal or diamond blade scalpel an in combination with other elements of the device is capable of shaving thin, shaped layers from the cornea of the eye, a procedure known as lamellar keratoplasty. The keratome is used to treat disease of the cornea as well as to correct vision deficiencies such as nearsightedness (myopia), farsightedness (hyperopia) and astigmatism by excising layers, either parallel or shaped, of the cornea in order to reshape the cornea to achieve proper focusing. In combination with a template of prescribed dimensions, the shape of the layer to be removed can be determined in advance.

Use of Proceeds

The proceeds from the proposed offering will be used for research and development of the HTK Keratome and the HRK Keratome, human clinical trials, repayment of indebtedness, working capital and general corporate purposes.

Last updated: 11/25/96